A5058311084- Diabetes Management and Research
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Pituitary Gland Disorders and Treatments
- Childhood Cancer Survivors' Quality of Life
- Cancer Diagnosis and Treatment
- Soft tissue tumor case studies
- Health, Medicine and Society
- Growth Hormone and Insulin-like Growth Factors
- Bone Tumor Diagnosis and Treatments
- Bone health and treatments
- Death, Funerary Practices, and Mourning
- Neurofibromatosis and Schwannoma Cases
- Adrenal and Paraganglionic Tumors
- Adolescent and Pediatric Healthcare
- Healthcare Systems and Practices
Centre Hospitalier Sud Francilien
2021-2024
Bicêtre Hospital
2018-2021
Hôpital de la Conception
2016-2017
Aix-Marseille Université
2017
Assistance Publique Hôpitaux de Marseille
2017
To evaluate the long-term metabolic outcomes and safety of hybrid closed loop (HCL) in youth living with type 1 diabetes, including people very poor control, this observational, retrospective, monocentric study included 101 patients aged 15-25 years. After a mean (±standard deviation; range) follow-up 16 (±6; 3-31) months, HbA1c decreased from 9.6% ± 2.3% (82 25 mmol/mol) at baseline to 8.0% 1.4% (64 15 (P < 0.001). Continuous glucose monitoring parameters showed same trend 0.001):...
Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin controlled. The aim our study was to determine whether a regular necessary in patients with long-term normal levels under DA.We conducted retrospective multicenter (Marseille, Paris La Pitie Salpetriere Nancy, France; Liege, Belgium) including macroprolactinomas (largest diameter: >10 mm baseline level:...
While hypothyroidism has frequently been reported with the use of TKIs, thyroid-stimulating hormone (TSH) suppressing effect TKIs is rare, except for thyroiditis. We describe a case progressive recurrent chordoma who initially became hyperthyroid in context autoimmunity under sorafenib treatment and later imatinib treatment. A 57-year-old man lumbar began daily 800 mg sorafenib. He did not have any other medication or recent iodinated-contrast exposure his family history was negative thyroid...
To evaluate the percentage of patients with type 1 diabetes (T1D) and very poor metabolic control who would agree to be treated a hybrid closed-loop (HCL) insulin delivery system, assess improvement safety. In single center, we identified all aged >18 years hemoglobin A1c (HbA1c) >11% (97 mmol/mol) before HCL treatment. We collected safety data up year post-HCL in those accepted after it was proposed them. 65 eligible for study, 32 (50%) already used, or start using HCL. Patients were 18-49...
Abstract Aims This study aimed to compare 12‐month metabolic outcomes in patients with type 1 diabetes (T1D) treated either MiniMed 780G (Guardian 4) or Control‐IQ (Dexcom G6) automated insulin delivery (AID) systems and identify interaction patient characteristics. Materials Methods We conducted a single‐centre, retrospective including all (aged ≥16) T1D who were started on between January 2021 October 2022 continued for ≥12 months. used propensity score matching the average marginal...
The transition from paediatric to adult diabetes care (TPA) of children/adolescents with type 1 (T1D) represents a unique challenge and remains critical phase in the T1D pathway. This study aims describe understand experience process participant's perspective young adults who are living France measure their satisfaction.